mirage

Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy

ABACUS/Manakin Repository

Show simple item record

dc.contributor.author López, José Ignacio
dc.contributor.author Pulido, Rafael
dc.contributor.author Cortés, Jesús M.
dc.contributor.author Angulo Cuesta, Javier
dc.contributor.author Lawrie, Charles H.
dc.date.accessioned 2018-11-06T11:30:15Z
dc.date.available 2018-11-06T11:30:15Z
dc.date.issued 2018
dc.identifier.citation López, J. I., Pulido, R., Cortés, J. M., Angulo, J. C., & Lawrie, C. H. (2018). Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy. Pathology-Research and Practice, 214(8), 1110-1114. http://dx.doi.org/10.1016/j.prp.2018.06.003 spa
dc.identifier.issn 0344-0338
dc.identifier.issn 1618-0631
dc.identifier.uri http://hdl.handle.net/11268/7547
dc.description.abstract Intratumor heterogeneity (ITH) detection remains a challenge in modern oncology because it can have a direct impact on the success of new therapies. Anti-PD-1/PD-L1 immunotherapy is an emerging treatment modality that is showing great promise for clear cell renal cell carcinoma (CCRCC) patients with advanced disease. Patient selection for such therapy relies upon the immunohistochemical detection of PD-1/PD-L1, however the degree of ITH for these markers among tumor cells and/or inflammatory mononuclear infiltrates remains unknown. Therefore, we analyzed PD-L1 (SP-142) expression in the tumor inflammatory cells of 22 CCRCC cases with the aim to define the pattern of PD-L1 expression, and to compare the reliability of current tumor sampling protocols (RS) with a multisite tumor sampling strategy (MSTS). While the RS protocol identified 5/22 (22.7%) of cases that were positive for PD-L1 expression, MSTS identified 10/22 (45.45%) of cases. This suggests that RS may miss a proportion of CCRCC patients that might benefit from immunotherapy. In addition, MSTS demonstrated that positive and negative regions of PD-L1 expression are very variable within each tumor. spa
dc.description.sponsorship SIN FINANCIACIÓN spa
dc.language.iso eng spa
dc.title Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy spa
dc.type article spa
dc.description.impact 1.466 JCR (2017) Q3, 55/79 Pathology spa
dc.identifier.doi 10.1016/j.prp.2018.06.003
dc.rights.accessRights closedAccess spa
dc.subject.uem Riñones spa
dc.subject.uem Cáncer spa
dc.subject.uem Células cancerosas spa
dc.subject.unesco Cáncer spa
dc.subject.unesco Célula spa
dc.description.filiation UEM spa
dc.peerreviewed Si spa


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record